Skip to main content
Premium Trial:

Request an Annual Quote

Incyte CEO Named to Aurora Biosciences Board

Premium

LA JOLLA, Calif.--Roy Whitfield, CEO of genomics and bioinformatics company Incyte Pharmaceuti cals, has joined the board of directors of Aurora Biosciences, a company here that designs and develops proprietary drug discovery systems, services, and technologies. Aurora's current collaborators include Bristol-Myers Squibb, Eli Lilly, Roche Bioscience, Sequana Therapeutics, and Allelix Bio pharmaceuticals.

Whitfield has served as CEO of Palo Alto-based Incyte since 1993. He has also been a director of the company since 1991 and was its president from 1991 until January of this year. Previously, he worked as a senior executive of Technicon Instruments and for the Boston Consulting Group.

Filed under

The Scan

Genome Sequences Reveal Range Mutations in Induced Pluripotent Stem Cells

Researchers in Nature Genetics detect somatic mutation variation across iPSCs generated from blood or skin fibroblast cell sources, along with selection for BCOR gene mutations.

Researchers Reprogram Plant Roots With Synthetic Genetic Circuit Strategy

Root gene expression was altered with the help of genetic circuits built around a series of synthetic transcriptional regulators in the Nicotiana benthamiana plant in a Science paper.

Infectious Disease Tracking Study Compares Genome Sequencing Approaches

Researchers in BMC Genomics see advantages for capture-based Illumina sequencing and amplicon-based sequencing on the Nanopore instrument, depending on the situation or samples available.

LINE-1 Linked to Premature Aging Conditions

Researchers report in Science Translational Medicine that the accumulation of LINE-1 RNA contributes to premature aging conditions and that symptoms can be improved by targeting them.